Document:

Unassociated Document

    Exhibit
10.10

    

    AMENDMENT
NO. 6 TO EXCLUSIVE LICENSE AGREEMENT

    

    AMENDMENT NO. 6 TO EXCLUSIVE LICENSE
AGREEMENT, dated August 30, 2010 (this “Amendment”), between
S.L.A. PHARMA AG (the
“Licensor”) and
VENTRUS BIOSCIENCES,
INC. (the “Licensee”), as
assignee of Paramount Biosciences, LLC (“Paramount”).

    

    WHEREAS, the Licensor and the
Licensee have entered into that certain Exclusive License Agreement, dated as of
March 23, 2007, as amended by Amendment No. 1 to Exclusive License Agreement
dated as of July 24, 2008, Amendment No. 2 to Exclusive License Agreement dated
as of November 20, 2008, Amendment No. 3 to Exclusive License Agreement dated as
of June 1, 2009, Amendment No. 4 to Exclusive License Agreement dated as of
December 18, 2009 (“Amendment No. 4”) and
Amendment No. 5 to Exclusive License Agreement dated as of June 24, 2010 (“Amendment No. 5”),
and as supplemented by those certain side letters dated as of October 27, 2008,
November 20, 2008, and January 22, 2009 (as amended, restated, supplemented or
otherwise modified to date the “License  Agreement”);

    

    WHEREAS, the parties hereto
desire to further amend the License Agreement as set forth herein.

    

    NOW, THEREFORE, in
consideration of the foregoing and for other consideration the sufficiency and
receipt of which is hereby acknowledged by the parties, it is hereby agreed by
and between the parties as follows:

    

    1.           Capitalized
Terms. Terms used herein but not otherwise defined shall have the meaning
ascribed thereto in the License Agreement.

    

    2.           Amendments.

    

    (a)           Given
Licensee’s continuing performance pursuant to the terms and conditions under
this Agreement, the License Agreement shall be in good standing and remain in
full force and effect.

    

    (b)           Effective
as of September 30, 2010, no additional Incostop Project Payments shall accrue
or otherwise be payable (excluding Incostop Project Payments due and payable
prior to September 30, 2010).  For the avoidance of doubt, Anoheal Project
Payments shall continue to be due and payable as set forth in Amendment No.
5.

    

    (c)           Upon
the execution of this Amendment, Licensee shall issue to Licensor a Warrant
substantially in the form attached hereto as Exhibit
A.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (d)           Section
2(f) of Amendment No 4. shall be deleted in its entirety.  For so long as
Licensee complies with the payment terms and conditions of this Amendment, then
Licensor shall not be entitled to terminate this License Agreement for
non-payment.  Licensor shall, however, be entitled to terminate the License
Agreement without notice and with immediate effect, if the Licensee has not
consummated a financing (or series of related financings) resulting in net
proceeds to it of at least US$10 million by December 31, 2010. 
Furthermore, Licensor shall be entitled to terminate the License Agreement with
one month’s notice in the event a third party wishes to enter into a license
agreement relating to Anoheal and Incostop and has entered into a binding
agreement with Licensor to that end. The termination shall however not become
effective if within the one month notice period Licensee pays all moneys
invoiced and unpaid as of such notice and the balance of the Maximum Anoheal
Amount (which in no event shall be the increased Maximum Anoheal Amount
described in Section 2(g) below, even if the events therein have occurred, i.e.
the Maximum Anoheal Amount will be $4,000,000).

    

    (e)           Schedule B of
Amendment No. 4 shall be amended to delete the October 31, 2010 payment date for
the $600,000 payment and replace it with December 31, 2010.

    

    (f)           
Schedule B of
Amendment No. 4 shall be amended to delete the February 28, 2011 payment date
for the $800,000 payment and replace it with the following: “within 14 calendar
days of Licensor providing Licensee with written notification of the completion
of enrollment into the Phase III Study of a Licensed Product incorporating
Anoheal API currently conducted by SLA in Europe (the “Phase III Anoheal
Study”).”

    

    (g)           Upon
the occurrence of the two (2) events set forth below, the “Maximum Anoheal
Amount” shall be increased to $4,400,000, and all references in the License
Agreement to the “Maximum Anoheal Amount” shall refer to such increased
amount:

    

    (1)
Licensee has received a quality-controlled final study report for such study;
and

    

    (2)
between October 1, 2010 and the date Licensee receives such report, Licensee
receives aggregate net proceeds of at least $20,000,000 (i) pursuant to one or
more equity financings or (ii) as up-front consideration for Licensee licensing
its intellectual property to a third party in connection with a partnering
agreement.

    

    (h)           Notwithstanding
anything to the contrary in the License Agreement, in the event Licensee,
pursuant to Section 23.2 of the License Agreement, terminates the License
Agreement (whether in its entirety or with respect to its rights and obligations
with respect to Licensed Products incorporating Anoheal or Incostop), Licensee’s
obligation to pay costs and expenses of performing work described in the
Licensor Clinical Development Plan or any amounts that are part of the Maximum
Anoheal Amount or Maximum Incostop Amount (including, without limitation,
payments set forth in Schedule B of Amendment No. 4) shall terminate as of the
date of Licensee’s notice of such termination (and not on the effective date of
termination), such that Licensee shall only be responsible for such payments
which have accrued prior to the date of such notice. For the avoidance of doubt,
Licensee shall be responsible for all costs (as defined in section...of the
License agreement) that have been actually incurred by Licensor in pursuance of
the Anoheal development plan that are in excess of the “Maximum Anoheal” amounts
already received by Licensor prior to the termination date.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (i)
           If (i) there
is Change of Control (as defined below) prior to the completion of the Phase III
Anoheal Study; and (ii) Licensee, pursuant to Section 23.2 of the License
Agreement, terminates the License Agreement within thirty (30) days following
the closing of the transaction resulting in the Change of Control, then Licensee
shall pay Licensor the balance of the Maximum Anoheal Amount (as increased per
Section 2(g) above) regardless of whether Licensor has incurred expenses equal
to such balance.  Such balance shall be paid within thirty (30) days
following the effective date of termination.  “Change of Control”
means a (i) a merger, share exchange or other reorganization in which the
stockholders of Licensee prior to such transaction do not own a majority of the
voting power of the acquiring, surviving or successor entity, (b) the sale by
one or more stockholders of a majority of the voting power of Licensee, or (c) a
sale of all or substantially all of the assets of Licensee related to the
subject matter of this License Agreement; provided, that, a Change of Control
shall not include a bona fide financing transaction in which voting control of
License transfers to one or more persons or entities who acquire shares of
Licensee’s capital stock in exchange for either an investment in Licensee or the
cancellation of indebtedness owed by Licensee, or a combination
thereof.

    

    (j) 
          If (i) there is
Change of Control following the completion of the Phase III Anoheal Study; and
(ii) Licensee, pursuant to Section 23.2 of the License Agreement, terminates the
License Agreement within thirty (30) days following the closing of the
transaction resulting in the Change of Control, then Licensee shall pay Licensor
(x) the balance of the Maximum Anoheal Amount (as increased per Section 2(g)
above) regardless of whether Licensor has incurred expenses equal to such
balance and (y) any other development expenses mutually agreed upon in writing,
but excluding Anoheal and Incostop Project Payments. Such amount shall be paid
within thirty (30) days following the effective date of
termination.

    

    3.           Counterparts.
This Amendment may be executed in any number of separate counterparts, each of
which shall be an original and all of which taken together shall constitute one
and the same instrument. Facsimile counterpart signatures to this Amendment
shall be acceptable and binding.

    

    4.           Applicable
Law. This Amendment shall he governed by and construed in accordance with
the laws of Switzerland without regard to principles of conflicts of
law.

    

    5.           Dispute
Resolution. All disputes arising out of or in connection with this
Amendment shall be resolved by the ordinary courts of Zurich, Switzerland,
without limiting the right of recourse.

    

    6.           No Other
Amendments. Except as expressly set forth herein, the License Agreement
remains in full force and effect in accordance with its terms and nothing
contained herein shall be deemed to be a waiver, amendment, modification or
other change of any term, condition or provision of the License Agreement. 
In the event of any conflict between the terms of this Amendment and any other
terms in the License Agreement, the terms of this Amendment shall
govern.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    7.           Effectiveness.
This Amendment shall become effective immediately upon the date
hereof.

    

    8.           References
to the License Agreement. From and after the date hereof, all references
in the License Agreement and any other documents to the License Agreement shall
be deemed to be references to the License Agreement after giving effect to this
Amendment.

    

    * * *
*

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    IN WITNESS WHEREOF, the
parties hereto have executed this Amendment No. 5 to Exclusive License Agreement
as of the date first written above.

    

    
      
        	
                By:

              	
                /s/ D. Slagel

              	 
      	
                By:

              	
                /s/ Russell H. Ellison

              
	 
      	
                Name:  D.
      Slagel

              	 
      	
                Name:  Chief
      Executive Officer

              
	 
      	
                Title:
      PRESIDENT

              	 
      	
                Title:  Russell
      H. Ellison

              

      

    

    

      
        
           

        

        
           

          
            

          

        

        
           

        

      

    Warrant
No.  ___ (CS-2010)

    

    EXHIBIT
A

    

    FORM OF
WARRANT

    

    VENTRUS
BIOSCIENCES, INC.

    COMMON
STOCK WARRANT

    

    As
partial consideration for Amendment No. 6 to the Exclusive License Agreement
between the parties, this certifies that S.L.A. Pharma AG (the “Holder”), its
designees or permitted assigns, subject to the terms and conditions set forth
herein, at any time after the Commencement Date and prior to the Expiration Date
(as such terms are defined below), is entitled to purchase from Ventrus
Biosciences, Inc., a Delaware corporation (the “Company”), 168,700 fully-paid and
non-assessable shares (subject to adjustment as provided herein) (the “Warrant Shares”) of
the Company’s Common Stock, $0.001 par value per share (the “Common Stock”), upon
surrender to the Company at its principal office (or at such other location as
the Company may advise the Holder in writing) of this Warrant properly endorsed
with the Form of Subscription attached hereto duly completed and signed and upon
payment of the aggregate Exercise Price (as defined below) for the number of
Warrant Shares for which this Warrant is being exercised determined in
accordance with the provisions hereof.  The exercise price (the “Exercise Price”) per
Warrant Share issuable pursuant to this Common Stock Warrant shall be equal to
$0.10 per share.

     

    This
Warrant is issued subject to the following terms and conditions:

     

    1.           Exercise, Issuance of
Certificates.  The Holder may exercise this Warrant, at any time or
from time to time, during the period (a) commencing at 5:00 p.m. (Eastern Time)
on August __,
2010 (the “Commencement Date”),
and (b) expiring at 5:00 p.m. (Eastern Time) on August __, 2013 (the
“Expiration
Date”).  The Holder may exercise this Warrant on or prior to the
Expiration Date for all or any part of the Warrant Shares (but not for a
fraction of a share) that may be purchased hereunder, as that number may be
adjusted pursuant to Section 3 of this Warrant.  The Company agrees that
the Warrant Shares purchased under this Warrant shall be and are deemed to be
issued to the Holder hereof as the record owner of such Warrant Shares as of the
close of business on the date on which this Warrant shall have been surrendered,
properly endorsed, the completed and executed Form of Subscription delivered,
and payment made for such Warrant Shares (such date, a “Date of
Exercise”).  Certificates for the Warrant Shares so purchased,
together with any other securities or property to which the Holder hereof is
entitled upon such exercise, shall be delivered to the Holder hereof by the
Company at the Company’s expense as soon as practicable after the rights
represented by this Warrant have been so exercised, but in any event not later
than ten (10) business days following the Date of Exercise.  In case of a
purchase of less than all the Warrant Shares which may be purchased under this
Warrant, the Company shall cancel this Warrant and execute and deliver to the
Holder hereof within a reasonable time a new Warrant or Warrants of like tenor
for the balance of the Warrant Shares purchasable under the Warrant surrendered
upon such purchase.  Each stock certificate so delivered shall be
registered in the name of such Holder and issued with a legend in substantially
the form of the legend placed below on this Warrant.

     

    (a)           The
Company’s obligations to issue and deliver Warrant Shares in accordance with the
terms hereof are absolute and unconditional, irrespective of any action or
inaction by the Holder to enforce the same.  Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver
certificates representing shares of Common Stock upon exercise of the
Warrant  as required pursuant to the terms hereof.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    (b)           Payment of Exercise
Price. The Holder shall pay the Exercise Price by delivering immediately
available funds to the Company.

     

    2.           Shares to be Fully Paid;
Reservation of Shares.  The Company covenants and agrees that all
Warrant Shares will, upon issuance and payment of the applicable Exercise Price,
be duly authorized, validly issued, fully paid and nonassessable, and free of
all preemptive rights, liens and encumbrances, except for restrictions on
transfer provided for herein.  The Company shall at all times reserve and
keep available out of its authorized and unissued Common Stock, solely for the
purpose of providing for the exercise of the rights to purchase all Warrant
Shares granted pursuant to this Warrant, such number of shares of Common Stock
as shall, from time to time, be sufficient therefor.

     

    3.           Adjustment of Exercise Price
and Number of Shares.  The Exercise Price and the total number of
Warrant Shares shall be subject to adjustment from time to time upon the
occurrence of certain events described in this Section 3.

     

    (a)           Subdivision or Combination
of Stock.  In the event the outstanding shares of the Company’s
Common Stock shall be increased by a stock dividend payable in Common Stock,
stock split, subdivision, or other similar transaction occurring after the date
hereof into a greater number of shares of Common Stock, the Exercise Price in
effect immediately prior to such subdivision shall be proportionately reduced
and the number of Warrant Shares issuable hereunder proportionately
increased.  Conversely, in the event the outstanding shares of the
Company’s Common Stock shall be decreased by reverse stock split, combination,
consolidation, or other similar transaction occurring after the date hereof into
a lesser number of shares of Common Stock, the Exercise Price in effect
immediately prior to such combination shall be proportionately increased and the
number of Warrant Shares issuable hereunder proportionately
decreased.

     

    (b)           Reclassification. 
If any reclassification of the capital stock of the Company or any
reorganization, consolidation, merger, or any sale, lease, license, exchange or
other transfer (in one transaction or a series of related transactions) of all
or substantially all, of the business and/or assets of the Company (the “Reclassification
Events”) shall be effected in such a way that holders of Common Stock
shall be entitled to receive stock, securities, or other assets or property,
then, as a condition of such Reclassification Event, lawful and adequate
provisions shall be made whereby the Holder hereof shall thereafter have the
right to purchase and receive (in lieu of the shares of Common Stock of the
Company immediately theretofore purchasable and receivable upon the exercise of
the rights represented hereby) such shares of stock, securities, or other assets
or property as may be issued or payable with respect to or in exchange for a
number of outstanding shares of such Common Stock equal to the number of shares
of such stock immediately theretofore purchasable and receivable upon the
exercise of the rights represented hereby.  In any Reclassification Event,
appropriate provision shall be made with respect to the rights and interests of
the Holder of this Warrant to the end that the provisions hereof (including,
without limitation, provisions for adjustments of the Exercise Price and of the
number of Warrant Shares), shall thereafter be applicable, as nearly as may be,
in relation to any shares of stock, securities, or assets thereafter deliverable
upon the exercise hereof.

     

    (c)           Notice of
Adjustment.  Upon any adjustment of the Exercise Price or any
increase or decrease in the number of Warrant Shares, the Company shall give
written notice thereof, by first class mail postage prepaid, addressed to the
registered Holder of this Warrant at the address of such Holder as shown on the
books of the Company.  The notice shall be prepared and signed by the
Company’s Chief Financial Officer and shall state the Exercise Price resulting
from such adjustment and the increase or decrease, if any, in the number of
shares purchasable at such price upon the exercise of this Warrant, setting
forth in reasonable detail the method of calculation and the facts upon which
such calculation is based.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    4.           No Voting or Dividend
Rights.  Nothing contained in this Warrant shall be construed as
conferring upon the holder hereof the right to vote or to consent to receive
notice as a stockholder of the Company on any other matters or any rights
whatsoever as a shareholder of the Company.  No dividends or interest shall
be payable or accrued in respect of this Warrant or the interest represented
hereby or the shares purchasable hereunder until, and only to the extent that,
this Warrant shall have been exercised.

     

    5.           Compliance with the
Act. The Holder of this Warrant, by acceptance hereof, agrees that this
Warrant is being acquired for its own account and not for any other person or
persons, for investment purposes and that it will not offer, sell, or otherwise
dispose of this Warrant except under circumstances which will not result in a
violation of the Act or any applicable state securities laws.

     

    6.           Limited
Transferability.  The Holder represents that by accepting this
Warrant it understands that this Warrant and any securities obtainable upon
exercise of this Warrant have not been registered for sale under Federal or
state securities laws and are being offered and sold to the Holder pursuant to
one or more exemptions from the registration requirements of such securities
laws.  In the absence of an effective registration of such securities or an
exemption therefrom, any certificates for such securities shall bear the legend
set forth on the first page hereof.  The Holder understands that it must
bear the economic risk of its investment in this Warrant and any securities
obtainable upon exercise of this Warrant for an indefinite period of time, as
this Warrant and such securities have not been registered under Federal or state
securities laws and therefore cannot be sold unless subsequently registered
under such laws, unless an exemption from such registration is available. THIS
WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”), OR
UNDER THE SECURITIES LAWS OF ANY STATE.  THIS WARRANT IS SUBJECT TO
RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD
EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS,
PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.  THE ISSUER OF THIS
WARRANT MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO
THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE
WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

     

    7.           Amendment, Waiver,
etc.  Except as expressly provided herein, neither this Warrant
nor any term hereof may be amended, waived, discharged or terminated other than
by a written instrument signed by the party against whom enforcement of any such
amendment, waiver, discharge or termination is sought.

     

    8.           Notices.  Any
notice, request, or other document required or permitted to be given or
delivered to the Holder hereof or the Company shall be delivered as set forth in
the Exclusive License Agreement.

     

    9.           Governing
Law.  This Warrant shall be construed and enforced in
accordance with, and the rights of the parties shall be governed by, the laws of
the State of New York without regard to the conflicts of laws provisions
thereof.

     

    10.         Lost or Stolen
Warrant.  Upon receipt of evidence reasonably satisfactory to
the Company of the loss, theft, destruction, or mutilation of this Warrant and,
in the case of any such loss, theft or destruction, upon receipt of an indemnity
reasonably satisfactory to the Company, or in the case of any such mutilation,
upon surrender and cancellation of such Warrant, the Company, at its expense,
will make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen,
destroyed or mutilated Warrant.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    11.         Fractional
Shares.  No fractional shares shall be issued upon exercise of
this Warrant.  The Company shall, in lieu of issuing any fractional
share, pay the Holder entitled to such fraction a sum in cash equal to such
fraction (calculated to the nearest 1/100th of a share) multiplied by the then
effective Exercise Price on the date the Form of Subscription is received by the
Company.

     

    12.         Successors and
Assigns.  This Warrant and the rights evidenced hereby shall
inure to the benefit of and be binding upon the successors of the Company and
the successors and assigns of the Holder.  The provisions of this
Warrant are intended to be for the benefit of all Holders from time to time of
this Warrant, and shall be enforceable by any such Holder.

     

    13.         Severability of
Provisions. In case any one or more of the provisions of this Warrant
shall be invalid or unenforceable in any respect, the validity and
enforceability of the remaining terms and provisions of this Warrant shall not
in any way be affected or impaired thereby and the parties will attempt in good
faith to agree upon a valid and enforceable provision which shall be a
commercially reasonable substitute therefor, and upon so agreeing, shall
incorporate such substitute provision in this Warrant.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
officer, thereunto duly authorized as of this ____ of August 2010.

    

    
      
        
          	 
      	
                  VENTRUS
      BIOSCIENCES, INC.

                
	 
      	 
      
	 
      	
                  By:

                	 
      
	 
      	
                  Name:
      Dr. Russell Ellison

                
	 
      	
                  Title:
      CEO

                

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    FORM
OF SUBSCRIPTION

     

    (To be
signed only upon exercise of Warrant)

     

    To:           Ventrus
Biosciences, Inc.

     

    The
undersigned, the holder of the attached Common Stock Warrant, hereby elects to
exercise the purchase right represented by such Warrant for, and to purchase
thereunder, _________________ shares of Common Stock of Ventrus Biosciences,
Inc. and such
holder herewith makes payment of $_________ therefor.

     

    The
undersigned requests that certificates for such shares be issued in the name of,
and delivered to:
__________________________________________________________________________________ whose address is:
______________________________________________________________________.

     

    
      
        
          
            
              
                
                  
                    
                      	
                              DATED:   

                            	 
      	 
      	 
      
	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                              (Signature
      must conform in all respects to name of

                            
	 
      	 
      	 
      	
                              Holder
      as specified on the face of the Warrant)

                            
	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                              Name:   

                            	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                              Title:Unassociated Document

     

    
      Exhibit
10.14

    

     

    
      VENTRUS
BIOSCIENCES, INC.

       

      2010
EQUITY INCENTIVE PLAN

       

      1.           Purpose.  The
purposes of this 2010 Equity Incentive Plan (the “Plan”) are:

      

      
        	
                 
      

              	
                ·

              	
                to
      attract and retain the best available personnel for positions of
      substantial responsibility;

              

      

      

      
        	
                 
      

              	
                ·

              	
                to
      provide additional incentives to directors, employees, and consultants of
      the Company; and

              

      

      

      
        	
                 
      

              	
                ·

              	
                to
      promote the success of the Company's business and the shareholders'
      interests.

              

      

      

      This Plan
is intended to provide incentives:

      

      (a) to employees of Ventrus
BioSciences, Inc. (the “Company”), or its parent (if any) or any of its present
or future subsidiaries (collectively, “Related Corporations”), by providing them
with opportunities to purchase Common Stock (as defined in Section 4) of the
Company pursuant to options granted hereunder that qualify as “incentive stock
options” (“ISOs”) under Section 422 of the Internal Revenue Code of 1986, as
amended, or any successor statute (the “Code”);

      

      (b) to directors, employees and
consultants of the Company and Related Corporations by providing them with
opportuni­ties to purchase Common Stock of the Company pursuant to options
granted hereunder that do not qualify as ISOs (Nonstatutory Stock Options, or
“NSOs”);

       

      (c) to directors, employees and
consultants of the Company and Related Corporations by providing them with a
right to receive the appreciation on Common Stock (“Stock Appreciation Rights”
or “SARs”);

      

      (d) to directors, employees and
consultants of the Company and Related Corporations by providing them with
restricted stock or bonus awards of Common Stock of the Company (“Stock
Bonuses”); and

      

      (e) to directors, employees and
consultants of the Company and Related Corporations by providing them with
opportunities to make direct purchases of Common Stock of the Company (“Purchase
Rights”).

      

      Both ISOs and NSOs are referred to
hereafter individually as “Options”, and Options, SARs, Stock Bonuses and
Purchase Rights are referred to hereafter collectively as “Stock
Rights”.  As used herein, the terms “parent” and “subsidiary” mean
“parent corporation” and “subsidiary corporation”, respectively, as those terms
are defined in Section 424 of the Code.

      

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

      2.           Administration of the
Plan.

      

      (a)           The
Plan shall be administered by (i) the Board of Directors of the Company (the
“Board”) or (ii) a committee consisting of directors or other persons appointed
by the Board (the “Committee”).  The appointment of the members of,
and the delegation of powers to, the Committee by the Board shall be consistent
with applicable laws and regulations (including, without limitation, the Code,
Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or any successor rule thereto (“Rule 16b-3”), the rules of
the Company’s primary stock exchange and any applicable state law (collectively,
the “Applicable Laws”)).  Once appointed, such Committee shall
continue to serve in its designated capacity until otherwise directed by the
Board.  From time to time, the Board may increase the size of the
Committee and appoint additional members thereof, remove members (with or
without cause) and appoint new members in substitution therefor, fill vacancies,
however caused, and remove all members of the Committee and thereafter directly
administer the Plan, all to the extent permitted by the Applicable
Laws.

      

      (b)           Subject
to ratification of the grant or authorization of each Stock Right by the Board
(if so required by an Applicable Law), and subject to the terms of the Plan, the
Committee, if so appointed, shall have the authority, in its discretion,
to:

      

      (i)
determine the employees of the Company and Related Corporations (from among the
class of employees eligible under Section 3 to receive ISOs) to whom ISOs may be
granted, and to determine (from among the classes of individuals and entities
eligible under Section 3 to receive NSOs, Stock Bonuses and Purchase Rights) to
whom NSOs, Stock Bonuses and Purchase Rights may be granted;

      

      (ii)
determine the time or times at which Options, Stock Bonuses or Purchase Rights
may be granted (which may be based on performance criteria);

      

      (iii)
determine the number of shares of Common Stock subject to any Stock Right
granted by the Committee;

      

      (iv)
determine the option price of shares subject to each Option, which price shall
not be less than the minimum price specified in Section 6 hereof, as
appropriate, and the purchase price of shares subject to each Purchase Right and
to determine the form of consideration to be paid to the Company for exercise of
such Option or purchase of shares with respect to a Purchase Right;

      

      (v)
determine whether each Option granted shall be an ISO or NSO;

      

      (vi)
determine (subject to Section 7) the time or times when each Option shall become
exercisable and the duration of the exercise period;

      

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

         

      

      (vii)
determine whether restrictions such as repurchase options are to be imposed on
shares subject to Options, Stock Bonuses and Purchase Rights and the nature of
such restrictions, if any;

      

      (viii)
approve forms of agreement for use under the Plan;

      

      (ix)
determine the fair market value of a Stock Right or the Common Stock underlying
a Stock Right, provided that the Committee shall not establish the fair market
value of a share of Common Stock as less than the fair market value as defined
pursuant to Section 6(d) below;

      

      (x)
accelerate vesting on any Stock Right, only in the cases of death, disability or
change in control, or to waive any forfeiture restrictions, or to waive any
other limitation or restriction with respect to a Stock Right;

      

      (xi)
reduce the exercise price of any Stock Right if the fair market value of the
Common Stock covered by such Stock Right shall have declined since the date the
Stock Right was granted (in accordance with any shareholder approval
requirements set forth in Section 17 below);

      

      (xii)
modify or amend each Stock Right (subject to Section 8(d) of the Plan) including
the discretionary authority to extend the post-termination exercisability period
of Stock Rights longer than is otherwise provided for by terms of the Plan or
the Stock Right;

      

      (xiii)
construe and interpret the Plan and Stock Rights granted hereunder and prescribe
and rescind rules and regulations relating to the Plan; and

      

      (xiv)
make all other determinations necessary or advisable for the administration of
the Plan.

      

      If the Committee determines to issue an
NSO, it shall take whatever actions it deems necessary, under Section 422 of the
Code and the regulations promulgated thereunder, to ensure that such Option is
not treated as an ISO.  The interpretation and construction by the
Committee of any provisions of the Plan or of any Stock Right granted under it
shall be final unless otherwise determined by the Board.  The
Committee may from time to time adopt such rules and regulations for carrying
out the Plan as it may deem best.  No member of the Board or the
Committee shall be liable for any action or determination made in good faith
with respect to the Plan or any Stock Right granted under it.

      

      (c)           The
Committee may select one of its members as its chairman, and shall hold meetings
at such times and places as it may determine.  Acts by a majority of
the Committee, approved in person at a meeting or in writing, shall be the valid
acts of the Committee.  All references in this Plan to the Committee
shall mean the Board if no Committee has been appointed.  From time to
time the Board may increase the size of the Committee and appoint additional
members thereof, remove members (with or without cause) and appoint new members
in substi­tution therefor, fill vacancies however caused, or remove all
members thereof and thereafter directly administer the Plan.

      

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

         

      

      (d)           Those
provisions of the Plan that make express reference to Rule 16b-3 shall apply to
the Company only at such time as the Company’s Common Stock is registered under
the Exchange Act, and then only to such persons as are required to file reports
under Section 16(a) of the Exchange Act (a “Reporting Person”).

      

      (e)           To
the extent that Stock Rights are to be qualified as “performance-based”
compensation within the meaning of Section 162(m) of the Code, the Plan shall be
administered by a committee consisting of two or more “outside directors” as
determined under Section 162(m) of the Code.

      

      (f)           Subject
to the provisions of the Plan and except to the extent prohibited by Applicable
Law, the Board or Committee may delegate to one or more individuals the
day-to-day administration of the Plan and any of the functions assigned to it in
this Plan.  Such delegation may be revoked at any time.

      

      (g)           The
decisions, determinations and interpretations of the administrator of the Plan
under paragraph 2(a) will be final and binding on all holders of Stock Rights
pursuant to the Plan.

      

      

      3.           Eligible Employees and
Others.

      

      (a)           Eligibility.  ISOs
may be granted to any employee of the Company or any Related
Corporation.  Those officers of the Company who are not employees may
not be granted ISOs under the Plan.  NSOs, Stock Bonuses and Purchase
Rights may be granted to any director, employee or consultant of the Company or
any Related Corporation. Granting of any Stock Right to any individual or entity
shall neither entitle that individual or entity to, nor disqualify him or her
from, participation in any other grant of Stock Rights.

      

      (b)           Special Rule for Grant of
Stock Rights to Reporting Persons.  The selection of a director
or an officer who is a Reporting Person (as the terms “director” and “officer”
are defined for purposes of Rule 16b-3) as a recipient of a Stock Right, the
timing of the Stock Right grant, the exercise price, if any, of the Stock Right
and the number of shares subject to the Stock Right shall be determined either
(i) by the Board, or (ii) by a committee of the Board that is composed solely of
two or more Non-Employee Directors having full authority to act in the
matter.  For the purposes of the Plan, a director shall be deemed to
be a “Non-Employee Director” only if such person is defined as such under Rule
16b-3(b)(3), as interpreted from time to time.

      

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

         

      

      4.           Stock.  The
stock subject to Stock Rights shall be authorized but unissued shares of Common
Stock of the Company, par value $0.001 per share, or such shares of the
Company’s capital stock into which such class of shares may be converted
pursuant to any reorganization, recapitalization, merger, consolidation or the
like (the “Common Stock”), or shares of Common Stock reacquired by the Company
in any manner.  The aggregate number of shares that may be issued
pursuant to the Plan is 2,467,200 shares of Common Stock, subject to adjustment
as provided herein.  Any such shares may be issued as ISOs, NSOs or
Stock Bonuses, or to persons or entities making purchases pursuant to Purchase
Rights, so long as the number of shares so issued does not exceed such aggregate
number, as adjusted.

      

      
        	
                 
      

              	
                (a)

              	
                If
      any Option granted under the Plan shall expire or terminate for any reason
      without having been exercised in full or shall cease for any reason to be
      exercisable in whole or in part, or if the Company shall reacquire any
      shares issued pursuant to Stock Rights, the unpurchased shares subject to
      such Options and any shares so reacquired by the Company shall again be
      available for grants of Stock Rights under the
  Plan.

              

      

      

      
        	
                 
      

              	
                (b)

              	
                In
      the event any Stock Option or other Award granted under the Plan is
      exercised through the tendering of shares of Common Stock (either actually
      or through attestation), or in the event tax withholding obligations are
      satisfied by tendering or withholding shares of Common Stock, any shares
      of Common Stock so tendered or withheld shall not again be available for
      Awards under the Plan.

              

      

      

      
        	
                 
      

              	
                (c)

              	
                The
      aggregate number of shares of Common Stock awarded to any Participant
      under the Plan pursuant to any Stock Right intended to be
      “performance-based compensation” within the meaning of Section 162(m) of
      the Code shall not exceed 1,233,600 shares in any three-year
      period.

              

      

      

      
        	
                 
      

              	
                (d)

              	
                Shares
      of Common Stock available for awards under the stockholder-approved plan
      of a company acquired by the Company (as adjusted, to the extent
      appropriate, using the exchange ratio or other adjustment or valuation
      ratio or formula used in such acquisition) may be used for Awards under
      the Plan to individuals who were not Eligible Participants prior to such
      acquisition and shall not count against the limit on the aggregate number
      of shares of Common Stock which are authorized for issuance under the
      Plan.

              

      

      

      
        	
                 
      

              	
                (e)

              	
                Shares
      of Common Stock reacquired by the Company on the open market or otherwise
      using cash proceeds from exercise of Stock Options shall not be available
      for Awards under the Plan.

              

      

      

      
        	
                 
      

              	
                (f)

              	
                The
      Company shall at all times reserve and keep available such number of
      shares of Common Stock as will be sufficient to satisfy the requirements
      of the Plan.

              

      

      

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

         

      

      5.           Granting of Stock
Rights.  Stock Rights may be granted under the Plan at any time
after the Effective Date, as set forth in Section 17, and prior to ten years
thereafter.  The date of grant of a Stock Right under the Plan will be
the date specified by the Board or Committee at the time it grants the Stock
Right; provided, however, that such date shall not be prior to the date on which
the Board or Committee acts.  The Board or Committee shall have the
right, with the consent of the optionee, to convert an ISO granted under the
Plan to an NSO pursuant to Section 18.

      

      6.           Minimum Price; ISO
Limitations.

      

      (a)           The
price per share specified in the agreement relating to each NSO, Stock Bonus or
Purchase Right granted under the Plan shall be established by the Board or
Committee at a price no less than fair market value, taking into account any
noncash consideration to be received by the Company from the recipient of Stock
Rights.

      

      (b)           The
price per share specified in the agreement relating to each Option granted under
the Plan shall not be less than the fair market value per share of Common Stock
on the date of such grant.  In the case of an ISO to be granted to an
employee owning stock possessing more than 10% of the total combined voting
power of all classes of stock of the Company or any Related Corporation, the
price per share specified in the agreement relating to such ISO shall not be
less than 110% of the fair market value per share of Common Stock on the date of
the grant.

      

      (c)           To
the extent that the aggregate fair market value (determined at the time an ISO
is granted) of Common Stock for which ISOs granted to any employee are
exercisable for the first time by such employee during any calendar year (under
all stock option plans of the Company and any Related Corporation) exceeds
$100,000, or such higher value as permitted under Code Section 422 at the time
of determination, such Options will be treated as NSOs, provided that this
Section shall have no force or effect to the extent that its inclusion in the
Plan is not necessary for Options issued as ISOs to qualify as ISOs pursuant to
Section 422 of the Code.  The rule of this Section 6(c) shall be
applied by taking Options in the order in which they were granted.

      

      (d)           If,
at the time a Stock Right is granted under the Plan, the Company’s Common Stock
is publicly traded, “fair market value” shall be determined as of the last
business day for which the prices or quotes discussed in this sentence are
available prior to the time such a Stock Right is granted and shall
mean:

      

      (i) if the Common Stock is then traded
on a national securities exchange, the closing sale price for the Common Stock
(or the closing bid, if no sales were reported as quoted on such exchange or
market); or

      

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

         

      

      (ii) the closing bid price or average
of bid prices last quoted on that date by an established quotation service, if
the Common Stock is not reported on a national securities exchange.

      

      However,
if the Common Stock is not publicly traded at the time a Stock Right is granted
under the Plan, “fair market value” shall be deemed to be the fair value of the
Common Stock as determined by the Board or Committee after taking into
consider­ation all factors that it deems appropriate.

      

      7.           Option
Duration.  Subject to earlier termination as provided in
Sections 10 and 11, each Option shall expire on the date specified by the Board
or Committee, but not more than:

      

      (a) ten (10) years from the date of
grant in the case of NSOs;

      

      (b) ten (10) years from the date of
grant in the case of ISOs generally; and

      

      (c) five (5) years from the date of
grant in the case of ISOs granted to an employee owning stock possessing more
than 10% of the total combined voting power of all classes of stock of the
Company or any Related Corpor­ation.

      

      Subject to earlier termination as
provided in Sections 10 and 11, the term of each ISO shall be the term set forth
in the original instrument granting such ISO, except with respect to any part of
such ISO that is converted into an NSO pursuant to Section 18.

      

      8.           Exercise of
Options.  Subject to the provisions of Section 10 through
Section 13 of the Plan, each Option granted under the Plan shall be exercisable
as follows:

      

      (a)           the
Option shall either be fully exercisable on the date of grant or shall become
exercisable thereafter in such installments as the Board or Committee may
specify;

      

      (b)           once
an installment becomes exercisable it shall remain exercisable until expiration
or termination of the Option, unless otherwise specified by the Board or
Committee;

      

      (c)           each
Option or installment may be exercised at any time or from time to time, in
whole or in part, for up to the total number of shares with respect to which it
is then exercisable; and

      

      (d)           the
Board or Committee shall have the right to accelerate the date of exercise of
any installment of any Option, provided that the Board or Committee shall not
accelerate the exercise date of any installment of any ISO granted to any
employee (and not previously converted into an NSO pursuant to Section 18)
without the prior consent of such employee if such acceleration would violate
the annual vesting limitation contained in Section 422 of the Code, as described
in Section 6(c).

      

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

         

      

      9.           Stock Appreciation
Rights.  Each SAR agreement shall be in such form and shall
contain such terms and conditions as the Board or Committee shall deem
appropriate.  SARs may be granted as stand-alone Stock Rights or in
tandem with other Stock Rights.  The terms and conditions of SAR
agreements may change from time to time, and the terms and conditions of
separate SAR agreements need not be identical; provided, however, that each
SAR agreement shall conform to (through incorporation of the provisions hereof
by reference in the agreement or otherwise) the substance of each of the
following provisions:

      

      (a)           Term.  No
SAR shall be exercisable after the expiration of ten (10) years from the
date of its grant or such shorter period specified in the SAR
agreement.

      

      (b)           Strike
Price.  Each SAR will be denominated in shares of Common Stock
equivalents.  The strike price of each SAR shall not be less than one
hundred percent (100%) of the fair market value of the Common Stock subject to
the SAR on the date of grant.

      

      (c)           Calculation of
Appreciation.  The appreciation distribution payable on the
exercise of a SAR will be not greater than an amount equal to the excess of
(A) the aggregate fair market value (on the date of the exercise of the
SAR) of a number of shares of Common Stock equal to the number of shares of
Common Stock equivalents in which the participant is vested under such SAR, and
with respect to which the participant is exercising the SAR on such date, over
(B) the strike price.

      

      (d)           Vesting.  At
the time of the grant of a SAR, the Board or Committee may impose such
restrictions or conditions to the vesting of such SAR as it, in its sole
discretion, deems appropriate.

      

      (e)           Exercise.  To
exercise any outstanding SAR, the participant must provide written notice of
exercise to the Company in compliance with the provisions of the SAR agreement
evidencing such SAR.

      

      (f)           Payment.  The
appreciation distribution in respect of a SAR may be paid in Common Stock, in
cash, in any combination of the two or in any other form of consideration, as
determined by the Board or Committee and set forth in the SAR agreement
evidencing SAR.

      

      (g)           Termination of Continuous
Service.  In the event that a participant's continuous service
terminates (other than For Cause, as defined in Section 10), the participant may
exercise his or her SAR (to the extent that the participant was entitled to
exercise such SAR as of the date of termination of continuous service) but only
within such period of time ending on the earlier of (A) the date three
(3) months following the termination of the participant's continuous
service (or such longer or shorter period specified in the SAR agreement), or
(B) the expiration of the term of the SAR as set forth in the SAR
agreement.  If, after termination of continuous service, the
participant does not exercise his or her SAR within the time specified herein or
in the SAR agreement (as applicable), the SAR shall terminate.

      

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

         

      

      (h)           Compliance with
Section 409A of the Code.  Notwithstanding anything to the
contrary set forth herein, any SARs granted under the Plan that are not exempt
from the requirements of Section 409A of the Code shall incorporate terms
and conditions necessary to avoid the consequences described in
Section 409A(a)(1) of the Code.  Such restrictions, if any, shall
be determined by the Board and contained in the SAR agreement evidencing such
SAR.

      

      10.           Termination of Employment or
Affiliation.  If a grantee ceases to be employed by the Company
and all Related Corporations other than by reason of death or disability as
defined in Section 11, or by reason of a termination “For Cause” as defined in
this Section 10, unless otherwise specified in Section 9 (in the case of SARs)
or in the instrument granting such Stock Right, the grantee shall have the
continued right to exercise any Stock Right held by him or her, to the extent of
the number of shares with respect to which he or she could have exercised it on
the date of termination until the date set forth in the Stock Right; provided,
however, in the event the grantee exercises any ISO after the date that is three
months following the date of termination of employment, such ISO will
automatically be converted into an NSO subject to the terms of the
Plan.  Employment shall be considered as continuing uninterrupted
during any bona fide leave of absence (such as those attributable to illness,
military obligations or governmental service) provided that the period of such
leave does not exceed ninety (90) days or, if longer, any period during which
such grantee’s right to reemployment with the Company is guaranteed by statute
or by contract.  A bona fide leave of absence with the written
approval of the Company shall not be considered an interruption of employment
under the Plan, provided that such written approval contractually obligates the
Company or any Related Corporation to continue the employment of the grantee
after the approved period of absence; provided that the foregoing approval
requirement shall not apply to a leave of absence guaranteed by statute or
contract. ISOs granted under the Plan shall not be affected by any change of
employment within or among the Company and Related Corporations, so long as the
optionee continues to be an employee of the Company or any Related
Corporation.

      

      For
purposes of this Plan, a change in status from employee to a consultant, or from
a consultant to employee, will not constitute a termination of employment,
provided that a change in status from an employee to consultant may cause an ISO
to become an NSO under the Code. In the event of a
termination “For Cause,” the right of a grantee to exercise a Stock Right shall
terminate as of the date of termination.  For purposes of this Plan,
“For Cause” shall mean the termination of a grantee’s status as an employee, a
director or consultant (as applicable) for any of the following reasons, as
determined by the Committee; provided, that, with respect to an employee that is
party to an agreement with the Company where a termination for cause is defined
in such agreement, the definition in such agreement shall govern the
determination under this Section 10:

      

      (i)           A
grantee who is a consultant and who commits a material breach of any consulting,
noncompetition, confidentiality or similar agreement with the Company or a
subsidiary, as determined under such agreement;

      

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

         

      

      (ii)           A
grantee who is an employee, director or a consultant and who is convicted
(including a trial, plea of guilty or plea of nolo contendere) for committing an
act of fraud, embezzlement, theft, or other act constituting a
felony;

      

      (iii)           A
grantee who is an employee, director or a consultant and who willfully engages
in gross misconduct or willfully violates a Company or a subsidiary policy which
is materially and demonstrably injurious to the Company and/or a subsidiary
after a written demand to cease such misconduct or violation has been delivered
by the Committee to the grantee that specifically identifies the manner in which
the Committee believes that the grantee has violated this Paragraph (iii), and
the grantee fails to cease such misconduct or violation and remedy any injury
suffered by the Company or the subsidiary as a result thereof within thirty (30)
calendar days after receiving such notice, unless the Board determines that a
shorter period of time is reasonable under the circumstances, provided, however,
that no act or failure to act, on the grantee’s part shall be considered
“willful” unless done, or omitted to be done, by the grantee not in good faith
and without reasonable belief that the grantee’s action or omission was in the
best interest of the Company or the subsidiary; or

      

      (iv)           A
grantee who is a Company or Related Corporation employee and who commits a
material breach of any noncompetition, confidentiality or similar agreement with
the Company or a Related Corporation, as determined under such
agreement.

      

      NOTHING IN THE PLAN SHALL BE DEEMED TO
GIVE ANY GRANTEE OF ANY STOCK RIGHT THE RIGHT TO BE RETAINED IN EMPLOYMENT OR
OTHER SERVICE BY THE COMPANY OR ANY RELATED CORPORATION FOR ANY PERIOD OF TIME
OR TO AFFECT THE AT-WILL NATURE OF ANY EMPLOYEE’S EMPLOYMENT.

      

      11.           Death;
Disability.

      

      (a)           If
a grantee ceases to be employed by or otherwise affiliated with the Company and
all Related Corporations by reason of death, or if a grantee dies within three
(3) months of the date his or her employment or other affiliation with the
Company has been terminated, any Stock Right held by him or her may be exercised
to the extent of the number of shares with respect to which he or she could have
exercised said Stock Right on the date of death, by his or her estate, personal
representative or beneficiary who has acquired the Stock Right by will or by the
laws of descent and distribution (the “Successor Grantee”), unless otherwise
specified in the instrument granting such Stock Right, prior to the earlier of
(i) one (1) year after the date of termination or (ii) the Stock Right’s
specified expiration date, provided, however, that a Successor Grantee shall be
entitled to ISO treatment under Section 421 of the Code only if the deceased
optionee would have been entitled to like treatment had he or she exercised such
Option on the date of his or her death provided, however, in the event the
Successor Grantee exercises an ISO after the date that is one (1) year following
the date of termination by reason of death, such ISO will automatically be
converted into a NSO subject to the terms of the Plan.

      

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

         

      

      (b)           If
a grantee ceases to be employed by or otherwise affiliated with the Company and
all Related Corporations by reason of disability, he or she shall continue to
have the right to exercise any Stock Right held by him or her on the date of
termination until, unless otherwise specified in the instrument granting such
Stock Right, the
earlier of (i) one (1) year after the date of termination or (ii) the Stock
Right’s specified expiration date, provided, however, in the event the grantee
exercises an ISO after the date that is one (1) year following the date of
termination by reason of disability, such ISO will automatically be converted
into a NSO subject to the terms of the Plan. For the purposes of the Plan, the
term “disability” shall mean “permanent and total disability” as defined in
Section 22(e)(3) of the Code.

      

      (c)           The
provisions of subsections (a) and (b) of this Section 11 regarding the exercise
period of a Stock Right may be waived, extended or further limited, in the
discretion of the Board or Committee, in an instrument granting a Stock Right
that is not an ISO.

      

      12.           Transferability and
Assignability of Stock Rights.

      

      (a)           No
ISO granted under this Plan shall be assignable or otherwise transferable by the
optionee except by will or by the laws of descent and
distribution.  An ISO may be exercised during the lifetime of the
optionee only by the optionee.

      

      (b)           Any
vested NSO or Purchase Right may be transferable by the grantee to the grantee’s
family members by will or by the laws of descent and distribution. For purposes
of the Plan, a grantee’s “family members” shall be deemed to consist of his or
her spouse, parents, children, grandparents, grandchildren and any trusts
created for the benefit of such individuals.  A family member to whom
any such Stock Right has been transferred pursuant to this Section 12(b) shall
be hereinafter referred to as a “Permitted Transferee”.  A Stock Right
shall be transferred to a Permitted Transferee in accordance with the foregoing
provisions, and subject to all the provisions of the Stock Right Agreement and
this Plan, by the execution by the grantee and the transferee of an assignment
in writing in such form approved by the Board or the Committee.  The
Company shall not be required to recognize the rights of a Permitted Transferee
until such time as it receives a copy of the assignment from the
grantee.

      

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

         

      

      13.           Terms and Conditions of
Stock Rights.  Stock Rights shall be evidenced by instruments
(which need not be identical) in such forms as the Board or Committee may from
time to time approve.  Such instruments shall conform to the terms and
conditions set forth in Sections 6 through 12 hereof and may contain such other
provisions as the Board or Committee deems advisable that are not inconsistent
with the Plan, including restrictions (which may be measurable performance
objectives established pursuant to this Plan for grantees  who have
received awards of performance-based Stock Rights, including, without
limitation, objectives which may be described in terms of company-wide
objectives or objectives that are related to the performance of the individual
grantee or of the subsidiary, division, department or function within the
Company in which the grantee is employed; objectives may be relative to the
performance of other companies; objectives applicable to any grantee may be
based upon specified levels of, or growth in, one of more of the following
criteria, determined either as an absolute number or percentage or in comparison
to the performance of specified companies or indices:  cash flow, EPS,
EBITDA, EBIT, net income, ROA, ROE, revenue, stock price, TSR, operating profit,
page views, impressions, unique visitors, or other conditions deemed by the
Board or Committee to be in the best interests of the Company) applicable to the
exercise of Options or to shares of Common Stock issuable upon exercise of
Options.  In granting any NSO, the Board or Committee may specify that
such NSO shall be subject to the restrictions set forth herein with respect to
ISOs, or to such other termination and cancellation provisions as the Board or
Committee may determine.  The Board or Committee may from time to time
confer authority and responsibility on one or more of its own members and/or one
or more officers of the Company to execute and deliver such
instruments.  The proper officers of the Company are authorized and
directed to take any and all action necessary or advisable from time to time to
carry out the terms of such instruments.

      

      14.           Adjustments.  Upon
the occurrence of any of the following events, the rights of a recipient of a
Stock Right granted here­under shall be adjusted as hereinafter provided,
unless otherwise provided in the written agreement between the recipient and the
Company relating to such Stock Right.

      

      (a)           If
the shares of Common Stock shall be subdivided or combined into a greater or
smaller number of shares or if the Company shall issue shares of Common Stock as
a stock dividend on its outstanding Common Stock, the number of shares of Common
Stock deliverable upon the exercise of outstanding Stock Rights shall be
appro­priate­ly increased or decreased proportionately, and
appro­priate adjustments shall be made in the purchase price (if any) per
share to reflect such subdivision, combination or stock dividend.

      

      (b)           If
the Company is to be consolidated with or acquired by another entity in a
merger, sale of all or substan­tially all of the Company’s assets or
otherwise (an “Acquisition”), unless otherwise provided by the Board or
Committee, in its sole discretion, the Board or Committee or the board of
directors of any entity assuming the obligations of the Company hereunder (the
“Successor Board”) shall, as to outstanding Stock Rights, make appropriate
provision for the continuation of such Stock Rights by either assumption of such
Stock Rights or by substitution of such Stock Rights with an equivalent award.
For Stock Rights that are so assumed or substituted, in the event of a
termination of grantee’s employment or consulting relationship by the Company or
its successor other than For Cause or by grantee for Good Reason (as defined
below) within sixty (60) days prior to and one hundred and eighty (180) days
after an Acquisition, all Stock Rights held by such grantee shall become vested
and immediately and fully exercisable and all forfeiture restrictions shall be
waived. If the Board, the Committee, or the Successor Board does not make
appropriate provisions for the continuation of such Stock Rights by either
assumption or substitution, unless otherwise provided by the Board or Committee
in its sole discretion, Stock Rights shall become vested and fully and
immediately exercisable and all forfeiture restrictions shall be waived and all
Stock Rights not exercised at the time of the closing of such Acquisition shall
terminate notwithstanding anything to the contrary in Section 10
hereof.  For purposes of this Plan, a termination for “Good Reason”
shall mean the resignation of an employee within thirty (30) days after the
following actions:  (i) without the express written consent of
employee, the Company assigns duties which are materially inconsistent with
employee’s position, duties and status; (ii) any action by the Company which
results in a material diminution in the position, duties or status of employee
or any transfer or proposed transfer of employee for any extended period to a
location  more than fifty (50) miles away from such employees’
principal place of employment, except for a transfer or proposed transfer for
strategic reallocations of the personnel reporting to employee; or (iii) the
Company reduces the base annual salary of employee, as then in
effect.

      

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

         

      

      (c)           In
the event of a transaction, including without limitation, a recapitalization or
reorganization of the Company (other than a transaction described in subsection
(b) above) pursuant to which securities of the Company are exchanged for other
securities, an optionee or grantee upon exercising a Stock Rights shall be
entitled to receive for the purchase price paid upon such exercise the
securities he or she would have received if he or she had exercised the Stock
Right immediately prior to such recapitalization or reorganization.

      

      (d)           In
the event of a spin-off from the Company or other non-cash dividend on the
outstanding shares of Common Stock, the Company will make appropriate equitable
adjustments to the exercise price of all outstanding Options and SARs, and to
the number of shares underlying such awards.

      

      (e)           In
the event of the proposed dissolution or liquidation of the Company, each Stock
Right will terminate immediately prior to the consummation of such proposed
action or at such other time and subject to such other conditions as shall be
determined by the Board or Committee.

      

      (f)           Except
as expressly provided herein, no issuance by the Company of shares of stock of
any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason thereof shall be made with respect to, the
number or price of shares subject to Stock Right.  No adjustments
shall be made for dividends paid in cash or in property other than Common Stock
of the Company, nor shall cash dividends or dividend equivalents accrue or be
paid in respect of unexercised Options or unvested Stock Rights
hereunder.

      

      (g)           No
fractional shares shall be issued under the Plan and any optionee who would
otherwise be entitled to receive a fraction of a share upon exercise of a Stock
Right shall receive from the Company cash in lieu of such fractional shares in
an amount equal to the fair market value of such fractional shares, as
determined in the sole discretion of the Board or Committee.

      

      (h)           Upon
the happening of any of the foregoing events described in subsections (a), (b)
or (c) above, the class and aggregate number of shares set forth in Section 4
hereof that are subject to Stock Rights that previously have been or
subsequently may be granted under the Plan shall also be appropriately adjusted
to reflect the events described.  The Board or Committee or the
Successor Board shall determine the specific adjustments to be made under this
Section 14 and, subject to Section 2, its determination shall be
conclusive.

      

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

         

      

      15.           Means of Exercising Stock
Rights.  Except as otherwise provided in this Plan or the
instrument evidencing the Stock Right, a Stock Right (or any part or installment
thereof) shall be exercised by giving written notice to the Company at its
principal office address to the attention of its Corporate
Secretary.  Such notice shall identify the Stock Right being exercised
and specify the number of shares as to which such Stock Right is being
exercised, accompanied by full payment of the exercise price therefor, if any,
payable as follows (a) in United States dollars in cash or by check, (b) at the
discretion of the Board or Committee, through the delivery of already-owned
shares of Common Stock having a fair market value equal as of the date of the
exercise to the cash exercise price of the Stock Right and, in the case of such
already-owned shares of Common Stock, having been owned by the participant for
more than six (6) months from the date of surrender, (c) at the discretion of
the Board or Committee, by delivery of the grantee’s personal recourse note
bearing interest payable not less than annually at a market rate that is no less
than 100% of the lowest applicable Federal rate, as defined in Section 1274(d)
of the Code, (d) at the discretion of the Board or Committee, through the
surrender of shares of Common Stock then issuable upon exercise of the Stock
Right having a fair market value on the date of exercise equal to the aggregate
price of the Stock Right, (e) at the discretion of the Board or Committee,
delivery of a notice that the grantee has placed a market sell order with a
broker with respect to shares of Common Stock then issuable upon exercise of the
Stock Right and that the broker has been directed to pay a sufficient portion of
the net proceeds of the sale to the Company in satisfaction of the Stock Right
Exercise Price, provided that payment of such proceeds is then made to the
Company upon settlement of the sale, or (f) at the discretion of the Board
or Committee, by any combination of (a), (b), (c), (d) and (e) or such other
consideration and method of payment for the issuance of shares to the extent
permitted by applicable law or the Plan. If the Board or Committee exercises its
discretion to permit payment of the exercise price of an ISO by means of the
methods set forth in clauses (b), (c) (d), (e) or (f) of the preceding sentence,
such discretion shall be exercised in writing at the time of the grant of the
ISO in question and such exercise shall also be governed by any terms set forth
in the written agreement evidencing the grant of the Stock Right.  The
holder of a Stock Right shall not have the rights of a stockholder with respect
to the shares covered by the Stock Right until the date of issuance of a stock
certificate for such shares.  Except as expressly provided above in
Section 14 with respect to changes in capitalization and stock dividends, no
adjustment shall be made for dividends or similar rights for which the record
date is before the date such stock certificate is issued.

      

      16.           Surrender of Stock Rights
for Cash or Stock.  The Board or Committee may, in its sole and
absolute discretion and subject to such terms and conditions as it deems
appropriate, accept the surrender by an optionee or grantee of a Stock Right
granted to him under the Plan and authorize payment in consideration therefor of
an amount equal to the difference between the purchase price payable for the
shares of Common Stock under the instrument granting the Option and the fair
market value of the shares subject to the Stock Right (determined as of the date
of such surrender of the Stock Right).  Such payment shall be made in
shares of Common Stock valued at fair market value on the date of such
surrender, or in cash, or partly in such shares of Common Stock and partly in
cash as the Board or Committee shall determine.  The surrender shall
be permitted only if the Board or Committee determines that such surrender is
consistent with the purpose set forth in Section 1, and only to the extent that
the Stock Right is exercisable under Section 8 on the date of
surrender.  In no event shall an optionee or grantee surrender his or
her Stock Right under this Section if the fair market value of the shares on the
date of such surrender is less than the purchase price payable for the shares of
Common Stock subject to the Stock Right.  Any ISO surrendered pursuant
to the provi­sions of this Section 16 shall be deemed to have been converted
into a NSO immediately prior to such surrender.

      

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

         

      

      17.           Term and Amendment of
Plan.  This Plan was adopted by the Board on August 4, 2010 and
by the stockholders of the Company on September 2, 2010 (the “Effective
Date”).  The Plan shall expire ten (10) years after the Effective Date
(except as to Stock Rights outstanding on that date).  The Board may
terminate or amend the Plan in any respect at any time, except that without the
approval of the stockholders obtained within twelve (12) months before or after
the Board adopts a resolution authorizing any of the following
actions:

      

      (a) the total number of shares that may
be issued under the Plan may not be increased (except by adjustment pursuant to
Section 14);

      

      (b) the provisions of Section 3
regarding eligibility for grants of ISOs may not be modified;

      

      (c) the provisions of Section 6(b)
regarding the exercise price at which shares may be offered pursuant to Options
may not be modified (except by adjustment pursuant to Section 14);

      

      (d) the expiration date of the Plan may
not be extended; and

      

      (e) except as provided in Section 13,
the Company may not amend an Option or SAR awarded under the Plan to reduce its
price per share, cancel and regrant new Options or SARs with lower prices per
share than the original prices per share of the cancelled Options or SARs, or
cancel any Options or SARs in exchange for cash or the grant replacement Awards
having the effect of a reprising without approval by the Company’s
shareholders.

      

      Except as provided in Section 14(b) and
this Section 17, in no event may action of the Board or stockholders adversely
alter or impair the rights of a grantee, without his or her consent, under any
Stock Right previously granted.  The approval of the stockholders of
the Company will be obtained as may be required by the applicable listing
regulations of any national securities exchange on which the Company’s Common
Stock may then be listed by the Company.

      

      
        
          
          

        

        
          15

          
            

          

        

        
          
          

        

         

      

      18.           Conversion of ISOs into
NSOs; Termination of ISOs; Forfeiture.

      

      (a)           The
Board or Committee, with the consent of any optionee, may in its discretion take
such actions as may be necessary to convert an optionee’s ISOs (or any
installments or portions of installments thereof) that have not been exercised
on the date of conversion into NSOs at any time prior to the expiration of such
ISOs.  These actions may include, but not be limited to, accelerating
the exercisability, extending the exercise period or reducing the exercise price
of the appropriate install­ments of optionee’s Options.  At the
time of such conversion, the Board or Commit­tee (with the consent of the
optionee) may impose these conditions on the exercise of the resulting NSOs as
the Board or Committee in its discretion may determine, provided that the
conditions shall not be inconsistent with the Plan.  Nothing in the
Plan shall be deemed to give any optionee the right to have such optionee’s ISOs
con­verted into NSOs, and no conversion shall occur until and unless the
Board or Committee takes appropriate action.  The Board or Committee,
with the consent of the optionee, may also terminate any portion of any ISO that
has not been exercised at the time of termination.

      

      (b)           If
the Board has reliable evidence of knowing misconduct by a Stock Right recipient
that resulted in the incorrect overstatement of the Company's earnings or other
financial measurements which were taken into consideration with respect to
management objectives, and the recipient received an award pursuant to this Plan
and such awards vested or became nonforfeitable as a result of such
overstatement, the Board may require that the recipient forfeit the full amount
of any awards granted pursuant to this Plan that resulted from such
overstatement.  For the avoidance of doubt, this provision shall not
apply to any awards granted pursuant to any other equity incentive
plans.  The remedy specified in this paragraph shall not be exclusive,
and shall be in addition to every other right or remedy at law or in equity that
may be available to the Company.

      

      19.           Governmental
Regulation.  The Company’s obligation to sell and deliver
shares of the Common Stock under the Plan is subject to the approval of any
governmental authority required in connection with the authorization, issuance
or sale of such shares.

      

      20.           Withholding of Additional
Income Taxes.

      

      (a)           Upon
the exercise of an NSO, or the grant of a Stock Bonus or Purchase Right for less
than the fair market value of the Common Stock, the making of a Disqualifying
Disposition (as defined in Section 21), the vesting of restricted Common Stock
acquired on the exercise of a Stock Right hereunder or the surrender of an
Option pursuant to Section 16, the Company, in accordance with Section 3402(a)
of the Code and any applicable state statute or regulation, may require the
optionee, Stock Bonus recipient or purchaser to pay to the Company additional
withholding taxes in respect of the amount that is considered compensation
includable in such person’s gross income.  With respect to (a) the
exercise of an Option, (b) the grant of a Stock Bonus, (c) the grant of a
Purchase Right of Common Stock for less than its fair market value, (d) the
vesting of restricted Common Stock acquired by exercising a Stock Right, or (e)
the acceptance of a surrender of an Option, the Committee in its discretion may
condition such event on the payment by the optionee, Stock Bonus recipient or
purchaser of any such additional withholding taxes.

      

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

         

      

      (b)           At
the sole and absolute discretion of the Committee, the holder of Stock Rights
may pay all or any part of the total estimated federal and state income tax
liability arising out of the exercise or receipt of such Stock Rights, the
making of a Disqualifying Disposition, or the vesting of restricted Common Stock
acquired on the exercise of a Stock Right hereunder (each of the foregoing, a
“Tax Event”) by tendering already-owned shares of Common Stock or (except in the
case of a Disqualifying Disposition) by directing the Company to withhold shares
of Common Stock otherwise to be transferred to the holder of such Stock Rights
as a result of the exercise or receipt thereof in an amount equal to the
estimated federal and state income tax liability arising out of such event,
provided that no more shares may be withheld than are necessary to satisfy the
holder’s actual minimum withholding obligation with respect to the exercise of
Stock Rights.  In such event, the holder of Stock Rights must,
however, notify the Committee of his or her desire to pay all or any part of the
total estimated federal and state income tax liability arising out of a Tax
Event by tendering already-owned shares of Common Stock or having shares of
Common Stock withheld prior to the date that the amount of federal or state
income tax to be withheld is to be determined.  For purposes of this
Section 20(b), shares of Common Stock shall be valued at their fair market value
on the date that the amount of the tax withholdings is to be
determined.

      

      21.           Notice to Company of
Disqualifying Disposition.  Each employee who receives an ISO
must agree to notify the Company in writing immediately after the employee makes
a Disqualifying Disposition (as defined below) of any Common Stock acquired
pursuant to the exercise of an ISO.  A “Disqualifying Disposition” is
any disposition (including any sale) of such Common Stock before either (a) two
(2) years after the date the employee was granted the ISO, or (b) one (1) year
after the date the employee acquired Common Stock by exercising the
ISO.  If the employee has died before such Common Stock is sold, these
holding period requirements do not apply and no Disqualifying Disposition can
occur thereafter.

      

      22.           Governing Law;
Construction.  The validity and construc­tion of the Plan
and the instruments evidencing Stock Rights shall be governed by the laws of the
State of Delaware.  In construing this Plan, the singular shall
include the plural and the masculine gender shall include the feminine and
neuter, unless the context otherwise requires.

      

      
        
          
          

        

        
          17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]